No black box warning on record for Asprin And Extended-Release Dipyridamole

As of the latest FDA labeling reviewed, Asprin And Extended-Release Dipyridamole (ASPRIN AND EXTENDED-RELEASE DIPYRIDAMOLE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Asprin And Extended-Release Dipyridamole medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Aspirin and extended-release dipyridamole capsules increase the risk of bleeding ( 5.1 ) • Avoid use in patients with severe hepatic or renal insufficiency ( 5.2 , 5.3 ) • Interrupt aspirin and extended-release dipyridamole capsules 48 hours before using intravenous dipyridamole or other adenosinergic agents for stress testing ( 5.6 , 7.1 ) 5.1 Risk of Bleeding Aspirin

No black box warning on record for Asprin And Extended-Release Dipyridamole

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Aspirin and extended-release dipyridamole capsules increase the risk of bleeding ( 5.1 ) • Avoid use in patients with severe hepatic or renal insufficiency ( 5.2 , 5.3 ) • Interrupt aspirin and extended-release dipyridamole capsules 48 hours before using intravenous dipyridamole or other adenosinergic agents for stress testing ( 5.6 , 7.1 ) 5.1 Risk of Bleeding Aspirin

Asprin And Extended-Release Dipyridamole Black Box Warning

No black box warning on record for Asprin And Extended-Release Dipyridamole

Other warnings & precautions

Asprin And Extended-Release Dipyridamole Black Box Warning

No black box warning on record for Asprin And Extended-Release Dipyridamole

Other warnings & precautions